Flumatinib mesylate Catalog No.:M9593-10 TAS0728 induces tumor regression in

TAS0728 induces tumor regression in mouse xenograft models bearing HER2 signal–dependent tumors and exhibits a survival benefit without any evident toxicity in a peritoneal dissemination mouse model bearing HER2-driven cancer cells

is a specific

A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks

Ropivacaine Hydrochloride Monohydrate causes reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the cell membrane of the nerve fibers

45(2):470-7

Flumatinib mesylate Catalog No.:M9593-10 TAS0728 induces tumor regression inFlumatinib, also known as HHGV678 , is a selective inhibitor of BCR ABL PDGFR KIT. Flumatinib is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). Flumatinib effectively overcomes drug resistance of certain KIT mutants. Flumatinib mesylate can reduce the expression of C MYC, HIF 1 and VEGF in U266 cell line in a time and dose dependent manners. Product information CAS Number: 895519 91 2